BR112015023738B8 - Vacinas de nucleoproteina influenza - Google Patents
Vacinas de nucleoproteina influenzaInfo
- Publication number
- BR112015023738B8 BR112015023738B8 BR112015023738A BR112015023738A BR112015023738B8 BR 112015023738 B8 BR112015023738 B8 BR 112015023738B8 BR 112015023738 A BR112015023738 A BR 112015023738A BR 112015023738 A BR112015023738 A BR 112015023738A BR 112015023738 B8 BR112015023738 B8 BR 112015023738B8
- Authority
- BR
- Brazil
- Prior art keywords
- influenza
- vaccines
- nucleoprotein
- influenza nucleoprotein
- variant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/11—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13305320.7 | 2013-03-18 | ||
| EP13305320 | 2013-03-18 | ||
| PCT/EP2014/055438 WO2014147087A1 (en) | 2013-03-18 | 2014-03-18 | Influenza nucleoprotein vaccines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112015023738A2 BR112015023738A2 (pt) | 2017-11-21 |
| BR112015023738B1 BR112015023738B1 (pt) | 2023-01-10 |
| BR112015023738B8 true BR112015023738B8 (pt) | 2023-02-14 |
Family
ID=48044708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015023738A BR112015023738B8 (pt) | 2013-03-18 | 2014-03-18 | Vacinas de nucleoproteina influenza |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9243047B2 (enExample) |
| EP (1) | EP2976357B1 (enExample) |
| JP (1) | JP2016520534A (enExample) |
| KR (1) | KR102379951B1 (enExample) |
| CN (2) | CN113307881A (enExample) |
| AU (1) | AU2014234363B2 (enExample) |
| BR (1) | BR112015023738B8 (enExample) |
| CA (1) | CA2901888C (enExample) |
| MX (1) | MX363149B (enExample) |
| RU (1) | RU2662667C2 (enExample) |
| WO (1) | WO2014147087A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015013387B8 (pt) * | 2012-12-11 | 2023-01-10 | Osivax Sas | Proteínas tipo coiled-coil modificadas possuindo propriedades melhoradas |
| EP3941519A4 (en) * | 2019-03-21 | 2023-01-18 | Georgia State University Research Foundation, Inc. | VIRUS-LIKE PARTICLES AND THEIR USES |
| JP2024532221A (ja) | 2021-08-24 | 2024-09-05 | オシバックス | 免疫原性組成物及びそれらの使用 |
| CA3242433A1 (en) | 2021-12-22 | 2023-06-29 | Osivax | Vaccine compositions and their use |
| AU2023237601A1 (en) | 2022-03-22 | 2024-09-05 | Osivax | Mrna vaccine compositions and their use |
| CN115779079A (zh) * | 2022-10-01 | 2023-03-14 | 中国人民解放军军事科学院军事医学研究院 | 一种可增强与佐剂协同免疫效力的电荷调控型抗原蛋白 |
| CN117659138B (zh) * | 2023-12-25 | 2025-04-08 | 华中农业大学 | 一种流感病毒np蛋白突变体及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL108915A0 (en) * | 1993-03-18 | 1994-06-24 | Merck & Co Inc | Polynucleotide vaccine against influenza virus |
| WO1999012036A1 (en) * | 1997-09-04 | 1999-03-11 | Stanford University | Reversible immobilization of arginine-tagged moieties on a silicate surface |
| WO2004016283A2 (en) * | 2002-08-14 | 2004-02-26 | Avidis Sa | Heteropolymeric compound comprising a scaffold, an adjuvant and an antigen, and its use |
| CN1867588A (zh) * | 2003-08-12 | 2006-11-22 | 阿维迪斯公司 | 包含c4bp核心蛋白质和单体抗原的产品及其用途 |
| EP1795540A1 (en) * | 2005-11-30 | 2007-06-13 | Imaxio | Multimeric complexes of antigens and an adjuvant |
| EP2060586A1 (en) * | 2007-11-14 | 2009-05-20 | PharmaSurgics in Sweden AB | New synthetic arginine substituted peptides and their use |
| GB0918154D0 (en) * | 2009-10-16 | 2009-12-02 | Isis Innovation | Mycobacterial vaccines |
| BR112015013387B8 (pt) * | 2012-12-11 | 2023-01-10 | Osivax Sas | Proteínas tipo coiled-coil modificadas possuindo propriedades melhoradas |
-
2014
- 2014-03-18 WO PCT/EP2014/055438 patent/WO2014147087A1/en not_active Ceased
- 2014-03-18 CA CA2901888A patent/CA2901888C/en active Active
- 2014-03-18 CN CN202110430609.2A patent/CN113307881A/zh active Pending
- 2014-03-18 CN CN201480013364.1A patent/CN105143251B/zh not_active Expired - Fee Related
- 2014-03-18 KR KR1020157029403A patent/KR102379951B1/ko active Active
- 2014-03-18 AU AU2014234363A patent/AU2014234363B2/en active Active
- 2014-03-18 MX MX2015013304A patent/MX363149B/es unknown
- 2014-03-18 JP JP2016503642A patent/JP2016520534A/ja active Pending
- 2014-03-18 BR BR112015023738A patent/BR112015023738B8/pt not_active IP Right Cessation
- 2014-03-18 RU RU2015140603A patent/RU2662667C2/ru active
- 2014-03-18 EP EP14710594.4A patent/EP2976357B1/en active Active
- 2014-12-15 US US14/570,155 patent/US9243047B2/en active Active
-
2015
- 2015-12-21 US US14/975,918 patent/US9963490B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150131292A (ko) | 2015-11-24 |
| MX363149B (es) | 2019-03-11 |
| CN105143251B (zh) | 2021-05-11 |
| BR112015023738A2 (pt) | 2017-11-21 |
| US9243047B2 (en) | 2016-01-26 |
| CA2901888A1 (en) | 2014-09-25 |
| EP2976357B1 (en) | 2018-10-17 |
| AU2014234363A1 (en) | 2015-09-03 |
| CA2901888C (en) | 2023-06-20 |
| RU2662667C2 (ru) | 2018-07-26 |
| RU2015140603A (ru) | 2017-04-21 |
| US9963490B2 (en) | 2018-05-08 |
| US20150098958A1 (en) | 2015-04-09 |
| EP2976357A1 (en) | 2016-01-27 |
| KR102379951B1 (ko) | 2022-03-31 |
| WO2014147087A1 (en) | 2014-09-25 |
| US20160215032A1 (en) | 2016-07-28 |
| MX2015013304A (es) | 2015-12-15 |
| JP2016520534A (ja) | 2016-07-14 |
| CN105143251A (zh) | 2015-12-09 |
| CN113307881A (zh) | 2021-08-27 |
| BR112015023738B1 (pt) | 2023-01-10 |
| AU2014234363B2 (en) | 2018-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015023738B8 (pt) | Vacinas de nucleoproteina influenza | |
| CY1122824T1 (el) | Πρωτεϊνες συντηξης και εμβολια συνδυασμου | |
| BR112017008165A2 (pt) | anticorpos de domínio único direcionados contra antígenos intracelulares | |
| BR112016015422A2 (pt) | formulações de vacina de frasco único | |
| BR112018012873A2 (pt) | vacina de vírus zika | |
| IL255106A0 (en) | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof | |
| MX2023003875A (es) | Formulacion de una vacuna peptidica. | |
| TR201908550T4 (tr) | Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi. | |
| BR112015030582A2 (pt) | Segmento de hemaglutinina da gripe quimérico e de neuraminidase quimérico, proteína de hemaglutinina quimérica, vírus da gripe rearranjado, métodos para preparação de um vírus da gripe rearranjado e para preparação de uma vacina e sistema de expressão | |
| WO2013106834A3 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
| BR112013030963A2 (pt) | proteína de fusão, polinucleotídio, constructo, vetor, célula hospedeira ou organismo, composição farmacêutica ou vacina, uso da proteína de fusão, método para prevenir ou tratar infecção hev ou doenças associadas com infecção hev, método para prevenir ou tratar infecção do vírus influenza e doenças associadas com a infecção do vírus influenza, método para melhorar a imunogenicidade de uma proteína alvo e uso de crm197 ou um fragmento do mesmo | |
| WO2015200357A3 (en) | Nucleic acids for treatment of peanut allergies | |
| MX2015011487A (es) | Proteinas de consenso para el virus de la enfermedad de la fiebre aftosa (fmdv), secuencias de codificacion para estas y vacunas elaboradas a partir de estas. | |
| EP3385286A4 (en) | VACCINE FANTASY WITH INCREASED IMMUNOGENITY | |
| BR112015025748A2 (pt) | construção de dna para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna | |
| MX362977B (es) | Vectores para la transformacion de mycoplasma hyopneumoniae, cepas transformadas de m. hyopneumoniae, y uso correspondiente. | |
| EP3939604A3 (en) | Influenza hemagglutinin protein vaccines | |
| BR112016019390A2 (pt) | proteínas de fusão uti | |
| BR112016019389A8 (pt) | Vacina, e, peptídeo | |
| BR112018008840A2 (pt) | anticorpos de domínio único direcionados contra antígenos intracelulares | |
| BR112014020025A2 (pt) | vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas | |
| WO2014140166A3 (en) | Vaccine | |
| IL254698A0 (en) | A vaccine based on the recombinant Jarl Lin mumps virus 2 | |
| PH12017501100B1 (en) | Recombinant swinepox virus and vaccines | |
| MX2019007924A (es) | Vacunas contra la influenza. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: OSIVAX SAS (FR) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/03/2014, OBSERVADAS AS CONDICOES LEGAIS |
|
| B09W | Correction of the decision to grant [chapter 9.1.4 patent gazette] |
Free format text: RETIFICA-SE O DEFERIMENTO NOTIFICADO NA RPI NO 2708 DE 29/11/2022. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2714 DE 10/01/2023 QUANTO AO QUADRO REIVINDICATORIO. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 12A ANUIDADE. |